Stocks to Buy: Nomura sees 28% upside in this Jhunjhunwala family-backed company

Global brokerage firm Nomura has initiated coverage on Inventurus Knowledge Solutions Ltd (IKS Health) with a 'Buy' rating and a price target of ₹2,000 per share.

The target suggests a potential upside of 28% from Friday's closing level.

The foreign brokerage wrote in its note that the US health care outsourcing market is likely to grow at a 12% CAGR over CY23 to CY28.

The brokerage described the company as an attractive play on the US healthcare provider ecosystem, referring to its long standing relationships with marquee enterprise clients.

Nomura expects IKS Health to deliver a 32% EPS CAGR over FY25 to FY28.

Jhunjhunwala family through three discretionary trusts—Nistha, Aryavir, and Aryaman—each holding a 16.37% stake in the company as of September 2025. Rekha Jhunjhunwala also holds a 0.23% stake in the company.

IKS Health, formally known as Inventurus Knowledge Solutions, provides a care enablement platform for physician enterprises across the US, Canada, and Australia, with a primary focus on the US market. It serves more than 778 healthcare organizations, including high-profile clients such as Mass General Brigham Inc., Texas Health Care PLLC, and The GI Alliance Management.

Of the six analysts that have coverage on IKS Health, four of them have a 'Buy' rating, while two others have a 'Hold' recommendation on the stock.

Shares of Inventurus Knowledge Solutions Ltd. closed 1.91% lower on Friday at ₹

1,560.10. The stock has declined 20% so far this year.